Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

NYU researchers identify novel therapy for rheumatoid arthritis

By enhancing the activity of immune cells that protect against runaway inflammation, researchers at NYU Langone Medical Center may have found a novel therapy for rheumatoid arthritis and other autoimmune diseases.

26 Mar 2010

Targeting Wnt/beta-catenin pathway may prevent growth and development of AML: Study

About 40 percent of children and up to 70 percent of adults in remission from acute myelogenous leukemia will have a relapse. In recent years, doctors have come to believe that this is due to leukemia stem cells, endlessly replicating cancer cells that generate the immature blood cells characteristic of leukemia and are resistant to typical cancer treatments.

26 Mar 2010

New gateway may be lifesaver for patients with AML: Study

Canadian researchers have discovered a previously hidden channel to attack leukemia and other cancer cells, according to a new study published in the Journal of Biological Chemistry. The findings from the Universit- de Montr-al, Maisonneuve-Rosemont Hospital and Universit- Laval may change the way doctors treat cancer patients.

26 Mar 2010

Biogen Idec and Elan begin comparative trial of MS treatments

Biogen Idec and Elan Corporation, plc (NYSE: ELN) today announced enrollment of the first patient in a global Phase IIIb, randomized, rater-blinded, active-controlled study designed to evaluate switching to TYSABRI® (natalizumab) from Copaxone® (glatiramer acetate) or Rebif® (interferon beta-1a) in patients with relapsing remitting multiple sclerosis.

25 Mar 2010

Æterna Zentaris announces 2009 financial and operating results

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the fourth quarter and the full year ended December 31, 2009.

24 Mar 2010

Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases

Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.

23 Mar 2010

Coalition of international health organizations oppose compensation for bone marrow donors

Voicing concern about the potential impact on patient and donor safety, nine leading international health organizations have formed a coalition to oppose compensating people who provide bone marrow for transplantation.

23 Mar 2010

CT colonography screening identifies unsuspected cancer outside of colon

A new, large-scale study of more than 10,000 adults found that more than one in every 200 asymptomatic people screened with CT colonography, or virtual colonoscopy, had clinically unsuspected malignant cancer and more than half of the cancers were located outside the colon. The findings were published in the April issue of the journal Radiology.

23 Mar 2010

$CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval$

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

Cell Therapeutics, Inc. announced today that the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee panel voted unanimously that clinical trial data was not adequate to support approval of pixantrone for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

23 Mar 2010

First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology and hematology, and TopoTarget A/S, today announced that the first patient has been dosed in a National Cancer Institute -sponsored Phase 1/2 trial of belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in the first line treatment of advanced or recurrent thymic malignancies.

22 Mar 2010

Zenyaku Kogyo receives license to Theraclone Sciences' influenza monoclonal antibody program

Theraclone Sciences, Inc., announced that Zenyaku Kogyo Co. Ltd., has exercised its option for an exclusive license in the Japan territory to Theraclone’s influenza monoclonal antibody program. The collaboration utilizes Theraclone’s I-STAR™ technology to discover broadly protective monoclonal antibodies for the treatment of pandemic influenza and severe seasonal influenza.

22 Mar 2010

ZIOPHARM Oncology reports fourth quarter net income of $1.0M against loss last year

ZIOPHARM Oncology, Inc., a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, announced today its financial results for the fourth quarter and full year 2009, and the filing of its Annual Report on Form 10-K with the Securities and Exchange Commission.

18 Mar 2010

Virtuoso Digital Pathology Software: BioImagene adds Companion Algorithms for colon cancer

BioImagene, Inc., the leading provider of end-to-end digital pathology solutions, today announced the availability of Companion Algorithms™ for colon cancer in their Virtuoso™ Digital Pathology Software. BioImagene’s Companion Algorithms are unique in the digital pathology industry as they are specific to a biomarker and a tissue type. Therefore, pathologists are not faced with the challenges of customizing generic algorithms in order to make them work.

18 Mar 2010

New findings promise to have fundamental significance in the fight against cancer

Cells have two different protection programs to safeguard them from getting out of control under stress and from dividing without stopping and developing cancer. Until now, researchers assumed that these protective systems were prompted separately from each other.

18 Mar 2010

Clarient's Ovotax test may help improve patients’ response to taxane therapy

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that data from a new study shows that Clarient's Ovotax™ assay may effectively predict which ovarian cancer patients will respond favorably to taxane therapy and could, therefore, be spared the potential side effects of this rigorous and sometimes toxic chemotherapy agent.

17 Mar 2010

Key cellular defect in protein synthesis can lead to cancer susceptibility

UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect.

17 Mar 2010

LLS, FORMA Therapeutics collaborate to develop small molecule compounds against Bcl-6

The Leukemia & Lymphoma Society and FORMA Therapeutics, Inc., today announced they have begun a partnership to discover and develop small molecule compounds against a key lymphoma target, Bcl-6.

15 Mar 2010

NCCN Guidelines and impact of escalating health care costs highlighted at NCCN Annual Conference

The escalating costs of cancer care combined with variations in concordance with evidence-based practice guidelines is putting the United States on a collision course for an impending collapse of its current health care system according to roundtable panelists at the NCCN 15th Annual Conference.

15 Mar 2010

New findings may help develop potential therapies for lupus, rheumatoid arthritis and cancer

Medical Research Council (MRC) scientists at the University of Leicester have made a new advance in understanding how the body fights certain types of cancer and other disease such as Lupus and rheumatoid arthritis.

15 Mar 2010

New PEGylated Polylysine dendrimers: Benefits patients with cancer, HIV and lymphatic conditions

Monash Institute of Pharmaceutical Science researchers, in collaboration with the biotechnology company Starpharma Holdings Ltd have developed a new method to deliver medications that may benefit thousands of patients with particular types of cancer, HIV and lymphatic conditions world-wide.

15 Mar 2010

Lymphoma News and Research

Further Reading

NYU researchers identify novel therapy for rheumatoid arthritis

Targeting Wnt/beta-catenin pathway may prevent growth and development of AML: Study

New gateway may be lifesaver for patients with AML: Study

Biogen Idec and Elan begin comparative trial of MS treatments

Æterna Zentaris announces 2009 financial and operating results

Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases

Coalition of international health organizations oppose compensation for bone marrow donors

CT colonography screening identifies unsuspected cancer outside of colon

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat

Zenyaku Kogyo receives license to Theraclone Sciences' influenza monoclonal antibody program

ZIOPHARM Oncology reports fourth quarter net income of $1.0M against loss last year

Virtuoso Digital Pathology Software: BioImagene adds Companion Algorithms for colon cancer

New findings promise to have fundamental significance in the fight against cancer

Clarient's Ovotax test may help improve patients’ response to taxane therapy

Key cellular defect in protein synthesis can lead to cancer susceptibility

LLS, FORMA Therapeutics collaborate to develop small molecule compounds against Bcl-6

NCCN Guidelines and impact of escalating health care costs highlighted at NCCN Annual Conference

New findings may help develop potential therapies for lupus, rheumatoid arthritis and cancer

New PEGylated Polylysine dendrimers: Benefits patients with cancer, HIV and lymphatic conditions

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News